The trial record versus the marketing claims
Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.
Every claim in the left column appears routinely on pages selling this peptide. The right column is what the cited record contains. Nothing here is an opinion about sellers; it is a column-by-column comparison against sources you can open.
| Dimension | What the trial and regulatory record shows | What is commonly claimed | Source |
|---|---|---|---|
| Fat loss in humans | The largest randomized trial, 24 weeks in 502 randomized obese adults, failed to show a significant benefit on the primary weight-loss endpoint. No human trial has ever reported a positive weight-loss result for this compound | Targeted fat loss, especially abdominal fat | source |
| Clinically studied | True, and that is the problem. About 900 adults took part in six trials. The trials were run, they finished, the efficacy did not hold, and the sponsor terminated the obesity program in 2007 | Backed by clinical trials in hundreds of patients | source |
| The fat-burning part of HGH | The fragment does not bind the growth hormone receptor and does not raise IGF-1 in humans. It also produced no measurable weight loss in humans. The side effects were avoided; so, on the human evidence, was the effect | All of growth hormone's fat-burning power without the side effects | source |
| Joint and cartilage repair | One study, in 32 rabbits with chemically induced knee osteoarthritis, using weekly ultrasound-guided injections directly into the joint. A 2026 review states that human clinical trial evidence for these indications is lacking | Repairs cartilage and rebuilds joints | source |
| The injections sold today | No human study of this molecule has ever used the subcutaneous route. The obesity trials used intravenous infusion or oral capsules and tablets; the later pain trials used oral capsules or intravenous infusion | Subcutaneous injection, roughly 250 to 500 mcg per day | source |
| Safety | Two things are both true. The trials found tolerability indistinguishable from placebo with no antibodies detected. FDA separately states it has identified no, or only limited, safety-related information, that it lacks sufficient information to know whether the drug would cause harm in humans, and that it has identified serious adverse events that may be associated with AOD-9604 though causality is not clear | Proven safe in clinical trials | source |
| Undetectable in drug tests | Correct but misleading. It does not influence the WADA hGH isoform immunoassay, which is precisely why anti-doping laboratories built dedicated assays that detect it in urine down to 50 pg/mL | Does not show up on growth hormone testing | source |